Delivery Order SPE2DB20D3103-SPE2DB25FM3K7

Award Date 1/15/25
Potential Completion Date 1/16/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $1,567.13 to provide VYVANSE 30 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The contract has an ultimate completion date of November 27, 2024 and is a Firm Fixed Price arrangement. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through November 2026, which serves as a primary...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of VYVANSE 50 MG CAPSULE 100S to the Defense Logistics Agency (DLA). The contract has a ceiling value of $2,455.93 and an ultimate completion date of January 3, 2025. It is a Delivery Order contract with a Firm Fixed Price pricing type. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant $999,999,999...
This federal contract award to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, with a ceiling value of $3,516.78, is for the delivery of 4,566,526,139 units of the pharmaceutical product VYVANSE 30 MG CAPSULE 100S. The contract is a Firm Fixed Price Delivery Order with a period of performance through November 25, 2024. This award is part of a larger Indefinite Delivery Contract (IDC)...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of 4567110043 - VYVANSE 30 MG CAPSULE 100S. The award has a ceiling value of $1,717.31 and is a firm fixed price delivery order contract with a completion date of January 31, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,129.72 Firm Fixed Price delivery order contract is for the provision of 4566831562 VYVANSE 20 MG CAPSULE 100S, with an ultimate completion date of December 31, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,635.68 firm fixed-price delivery order is for the supply of VYVANSE 70 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 10, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VYVANSE 30 MG CAPSULE 100S, with a ceiling value of $1,166.06 and a period of performance extending to June 23, 2025. The contract is a Firm Fixed Price Delivery Order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of VYVANSE CAPS 50MG, a pharmaceutical product, and has a ceiling value of $34,354.33. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the period of performance runs through January 24, 2025. Amerisourcebergen holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,902.66 Firm Fixed Price delivery order is for the supply of VYVANSE 20 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 25, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,153.73, is a firm fixed-price delivery order for the supply of VYVANSE 40 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of March 12, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FM3K7
    Delivery Order

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the provision of VYVANSE 50 MG CAPSULE 100S. The award has a ceiling value of $1,427.48 and is a Firm Fixed Price Delivery Order contract. The contract has an ultimate completion date of January 16, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award does not have a set-aside designation, indicating open competition.

Generated 4/17/25, 8:53 AM